RxDoctor Payments Data

Stuart Klein, MD

Internal Medicine · Poway, CANPI 1104834472

Payments from drug & device makers

$11,528in general payments, 2019–2025

Across 501 payments — averaging $23.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biohaven Pharmaceutical Holding Company Ltd.$2K
  • AbbVie$2K
  • GSK$1K
  • AstraZeneca$996
  • Lilly USA, LLC$694
  • Merck$469
  • plus $5K from 46 others

What the payments were for

  • Consulting fees$1,20010%
  • Food & beverage$10,25789%
  • Education$711%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,528 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$68,413
Medicare patients
178
Services billed
15,478

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban49$46,981
OzempicSemaglutide22$44,628
Trelegy ElliptaFluticasone/Umeclidin/Vilanter34$29,623
JardianceEmpagliflozin16$22,585
XareltoRivaroxaban11$17,400
JanuviaSitagliptin Phosphate11$15,540
Janumet XrSitagliptin Phos/Metformin Hcl16$14,500
FarxigaDapagliflozin Propanediol16$12,565
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl35$6,987
Bevespi AerosphereGlycopyrrolate/Formoterol Fum12$5,343
Testosterone12$5,092
OxycontinOxycodone Hcl11$4,458
Atorvastatin Calcium307$3,265
Trazodone Hcl128$3,026
PaxlovidNirmatrelvir/Ritonavir19$2,858

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$399$49,84068 claims
Novo NordiskOzempic$389$44,62822 claims
MerckJanuvia, Janumet Xr$469$30,04127 claims
GSKTrelegy Ellipta$1,057$29,62334 claims
Boehringer IngelheimJardiance$86$22,58516 claims
AstraZenecaFarxiga, Bevespi Aerosphere$996$17,90828 claims
Johnson & JohnsonXarelto$32$17,40011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Poway

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →